Lenalidomide hydrochloride monohydrateProduct ingredient for Lenalidomide

Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.⁴ It is a 4-amino-glutamyl analogue of thalidomide ³ and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.⁷ However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.^2,3 Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity.⁷ Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in selected patients.⁹ Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.⁷